NTLA — Intellia Therapeutics, Inc.

Is NTLA overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

Intellia Therapeutics, Inc. (NTLA) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $9.86. The rating moved from Neutral to Oversold on November 3, 2026.

See all oversold Healthcare stocks →

AI analysis

Intellia Therapeutics, Inc. (NTLA) is a leader in in‑vivo CRISPR gene editing with meaningful scientific upside from early clinical programs and strategic partner optionality. Financial health depends on near‑term cash runway and potential non‑dilutive deals; capital needs are a key driver of share volatility. Current market tone is cautious, reducing appetite for speculative biotech moves in the immediate session. Overall near‑term outlook is binary: clinical/regulatory progress could unlock upside, while financing, safety, or execution issues would increase downside risk.

Key factors

  • Platform leadership in in vivo CRISPR gene editing with multiple clinical-stage programs and differentiated delivery technology.
  • Partnerships and potential deal flow with larger pharma/biotech that can de‑risk development and provide non-dilutive capital.
  • Pipeline catalysts over the coming quarters (early‑stage readouts) that could materially re‑rate investor expectations.
  • Cash runway and recent financing posture — balance between R&D spend and available liquidity will drive near‑term financing/dilution risk.
  • Competitive environment including other gene-editing companies (CRISPR Therapeutics, Editas) and alternative modalities (base editing, AAV gene therapy).
  • Macro environment: cautious risk-on tone and rotation to defensives reduces speculative biotech appetite in the near term.

Risks

  • Clinical trial disappointment or safety events in first‑in‑human in vivo CRISPR programs, triggering sharp share price declines.
  • Regulatory uncertainty for genome editing therapies, including evolving guidelines and longer approval timelines.
  • Intellectual property disputes or limitations that could constrain freedom to operate or force expensive licensing.
  • Dilution from equity raises if cash runway proves short of requirements to advance multiple programs.
  • Manufacturing scale‑up challenges and cost overruns for complex delivery platforms (LNP/AAV manufacturing constraints).
  • Competition executing faster or delivering superior efficacy/safety profiles, reducing commercial opportunity.
  • Reimbursement and commercialization risk for novel curative or one‑time therapies, including pricing pushback by payors.

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for NTLA — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.